Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Radiation immunomodulatory gene tumor therapy of rats with intracerebral glioma tumors.

Persson, Bertil R LU orcid ; Baureus Koch, Catrin ; Grafström, Gustav LU ; Ceberg, Crister LU orcid ; Munck af Rosenschöld, Per LU orcid ; Nittby, Henrietta LU ; Widegren, Bengt LU and Salford, Leif LU (2010) In Radiation Research 173(4). p.433-440
Abstract
Single-fraction radiation therapy with 5 or 15 Gy (60)Co gamma radiation was combined with intraperitoneal injections of syngeneic interferon gamma (IFN-gamma)-transfected cells in rats with intracerebral N29 or N32 glioma tumors at days 7, 21 and 35 after inoculation. For intracerebral N29 tumors, single-fraction radiation therapy with 5 or 15 Gy had no significant effect on the survival time. Immunization with IFN-gamma-transfected N29 cells significantly increased the survival time by 61%. Single-fraction radiation therapy with 5 Gy combined with immunization increased the survival time significantly by 87% and complete remissions by 75% while with 15 Gy the survival time increased 45% with 38% complete remissions. For intracerebral N32... (More)
Single-fraction radiation therapy with 5 or 15 Gy (60)Co gamma radiation was combined with intraperitoneal injections of syngeneic interferon gamma (IFN-gamma)-transfected cells in rats with intracerebral N29 or N32 glioma tumors at days 7, 21 and 35 after inoculation. For intracerebral N29 tumors, single-fraction radiation therapy with 5 or 15 Gy had no significant effect on the survival time. Immunization with IFN-gamma-transfected N29 cells significantly increased the survival time by 61%. Single-fraction radiation therapy with 5 Gy combined with immunization increased the survival time significantly by 87% and complete remissions by 75% while with 15 Gy the survival time increased 45% with 38% complete remissions. For intracerebral N32 tumors, single-fraction radiation therapy with 15 Gy increased the survival time significantly by 20%. Immunization by itself had no significant effect with IFN-gamma-transfected N32 cells, but combined with 15 Gy single-fraction radiation therapy it increased survival time significantly by 40%, although there were no complete remissions. Based on these findings, we suggest a new therapeutic regimen for malignant glioma using single-fraction radiation therapy with a target absorbed dose of the order of 5-10 Gy combined with clinically verified immunotherapy. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Radiation Research
volume
173
issue
4
pages
433 - 440
publisher
Radiation Research Society
external identifiers
  • wos:000276472800005
  • pmid:20334515
  • scopus:77950289842
ISSN
0033-7587
DOI
10.1667/RR1733.1
language
English
LU publication?
yes
id
69e957cb-0f30-4dd4-a59a-4c5c9583c911 (old id 1581720)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20334515?dopt=Abstract
date added to LUP
2016-04-04 09:19:11
date last changed
2023-07-20 08:31:41
@article{69e957cb-0f30-4dd4-a59a-4c5c9583c911,
  abstract     = {{Single-fraction radiation therapy with 5 or 15 Gy (60)Co gamma radiation was combined with intraperitoneal injections of syngeneic interferon gamma (IFN-gamma)-transfected cells in rats with intracerebral N29 or N32 glioma tumors at days 7, 21 and 35 after inoculation. For intracerebral N29 tumors, single-fraction radiation therapy with 5 or 15 Gy had no significant effect on the survival time. Immunization with IFN-gamma-transfected N29 cells significantly increased the survival time by 61%. Single-fraction radiation therapy with 5 Gy combined with immunization increased the survival time significantly by 87% and complete remissions by 75% while with 15 Gy the survival time increased 45% with 38% complete remissions. For intracerebral N32 tumors, single-fraction radiation therapy with 15 Gy increased the survival time significantly by 20%. Immunization by itself had no significant effect with IFN-gamma-transfected N32 cells, but combined with 15 Gy single-fraction radiation therapy it increased survival time significantly by 40%, although there were no complete remissions. Based on these findings, we suggest a new therapeutic regimen for malignant glioma using single-fraction radiation therapy with a target absorbed dose of the order of 5-10 Gy combined with clinically verified immunotherapy.}},
  author       = {{Persson, Bertil R and Baureus Koch, Catrin and Grafström, Gustav and Ceberg, Crister and Munck af Rosenschöld, Per and Nittby, Henrietta and Widegren, Bengt and Salford, Leif}},
  issn         = {{0033-7587}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{433--440}},
  publisher    = {{Radiation Research Society}},
  series       = {{Radiation Research}},
  title        = {{Radiation immunomodulatory gene tumor therapy of rats with intracerebral glioma tumors.}},
  url          = {{http://dx.doi.org/10.1667/RR1733.1}},
  doi          = {{10.1667/RR1733.1}},
  volume       = {{173}},
  year         = {{2010}},
}